Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets

American Journal of Gastroenterology

Volumn 95, Issue 7, 2000, Pages 1669-1676

  Reid, Brian J ^a,b   Levine, Douglas S ^b   Longton, Gary ^a   Blount, Patricia L ^a,b   Rabinovitch, Peter S ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER RISK; EARLY DIAGNOSIS; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; GASTROESOPHAGEAL REFLUX; HIGH RISK POPULATION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOPSY; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PLOIDIES; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0033915683     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00988-6     Document Type: Article

References (56)

1. Locke G.R. III, Talley N.J., Fett S.L., et al. Prevalence and clinical spectrum of gastroesophageal reflux A population-based study in Olmsted County, Minnesota . Gastroenterology. 112:1997;1448-1456.
2. Winters C. Jr, Spurling T.J., Chobanian S.J., et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 92:1987;118-124.
3. Spechler S.J., Zeroogian J.M., Antonioli D.A., et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 344:1994;1533-1536.
4. Reid B.J. Barrett's esophagus and esophageal adenocarcinoma. Roy Wong K.H. Gastroenterology Clinics of North America Mucosal diseases of the esophagus . 1991;817-834 WB Saunders, Philadelphia.
5. Devesa S.S., Blot W.J., Fraumeni J.F. Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 83:1998;2049-2053.
6. Powell J., McConkey C.C. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev. 1:1992;265-269.
7. Farrow D.C., Vaughan T.L. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control. 7:1996;322-327.
8. Peters J.H., Clark G.W., Ireland A.P., et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 108:1994;813-821.
9. Levine D.S., Haggitt R.C., Blount P.L., et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology. 105:1993;40-50.
10. van der Burgh A., Dees J., Hop W.C., et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut. 39:1996;5-8.
11. Drewitz D.J., Sampliner R.E., Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus A prospective study of 170 patients followed 4.8 years . Am J Gastroenterol. 92:1997;212-215.
12. Miros M., Kerlin P., Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut. 32:1991;1441-1446.
13. Cameron A.J., Ott B.J., Payne W.S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med. 313:1985;857-859.
14. Spechler S.J., Robbins A.H., Rubins H.B., et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology. 87:1984;927-933.
15. Hameeteman W., Tytgat G.H.J., Houthoff H.J., van den Tweel J.G. Barrett's esophagus Development of dysplasia and adenocarcinoma . Gastroenterology. 96:1989;1249-1256.
16. Robertson C.S., Mayberry J.F., Nicholson D.A., et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg. 75:1988;760-763.
17. Williamson W.A., Ellis F.H., Gibb P., et al. Barrett's esophagus Prevalence and incidence of adenocarcinoma . Arch Intern Med. 151:1991;2212-2216.
18. Ovaska J., Miettinen M., Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci. 34:1989;1336-1339.
19. Achkar E., Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol. 3:1988;291-294.
20. O'Connor B.J., Falk G.W., Richter J.E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus. Am J Gastroenterol. 94:1999;2037-2042.
21. Grimm I., Shaheen N., Bozymski E.M. Surveillance for Barrett's esophagus Are we saving lives? Gastroenterology. 112:1997;661-662.
22. Cameron A.J. Barrett's esophagus Does the incidence of adenocarcinoma matter? Am J Gastroenterol. 92:1997;193-194.
23. Falk G.W., Ours T.M., Richter J.E. Practice patterns for surveillance of Barrett's esophagus in the USA. Gastrointest Endosc. 49:1999;AB50. (abstract).
24. Provenzale D., Schmitt C., Wong J.B. Barrett's esophagus A new look at surveillance based on emerging estimates of cancer risk . Am J Gastroenterol. 94:1999;2043-2053.
25. Sampliner R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 93:1998;1028-1032.
26. Reid B.J., Haggitt R.C., Rubin C.E., et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 19:1988;166-178.
27. Sagan C., Flejou J.F., Diebold M.D., et al. Observer variation in the diagnosis of dysplasia in Barrett's mucosa. Gastroenterol Clinic Biol. 18:1994;D31-D34.
28. Polkowski W., Baak J.P.A., Van Lanshot J.J.B., et al. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol. 184:1998;161-168.
29. Alikhan M., Rex D., Khan A., et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 50:1999;23-26.
30. van Leishout E.M., Jansen J.B., Peters W.H. Biomarkers in Barrett's esophagus. Int J Oncol. 13:1998;855-864.
31. Reid B.J., Haggitt R.C., Rubin C.E., et al. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology. 93:1987;1-11.
32. Fennerty M.B., Sampliner R.E., Way D., et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology. 97:1989;815-820.
33. Robaszkiewicz M., Hardy E., Volant A., et al. Analyse du contenu cellulaire en ADN par cytometrie en flux dans les endobrachyoesophages. Etude de 66 cas. Gastroenterol Clin Biol. 15:1991;703-710.
34. Garewal H.S., Sampliner R.E., Fennerty M.B. Flow cytometry in Barrett's esophagus. Dig Dis Sci. 36:1991;548-551.
35. Herman R.D., McKinley M.J., Bronzo R.L., et al. Flow cytometry and Barrett's esophagus. Dig Dis Sci. 37:1992;635-637.
36. Teodori L., Gohde W., Persiani M., et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus Thirteen-year follow-up study on a cohort of patients . Cytometry. 34:1998;257-263.
37. Galipeau P.C., Cowan D.S., Sanchez C.A., et al. 17p (p53) Allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA. 93:1996;7081-7084.
38. Reid B.J., Blount P.L., Rubin C.E., et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus Prospective endoscopic surveillance of a cohort . Gastroenterology. 102:1992;1212-1219.
39. Levine D.S., Reid B.J. Endoscopic diagnosis of esophageal neoplasms. Boyce G.A., Boyce H.W. Jr. Gastrointest Endosc Clin North Am. 1992;395-413 WB Saunders, Philadelphia.
40. Haggitt R.C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 25:1994;982-993.
41. Rabinovitch P.S. DNA content histogram and cell-cycle analysis. Methods Cell Biol. 41:1994;263-296.
42. Alanen K.A., Joensuu H., Klemi P.J. Autolysis is a potential source of false aneuploid peaks in flow cytometric DNA histograms. Cytometry. 10:1989;417-425.
43. Kalbfleish J.D., Prentice R.L. The statistical analysis of failure time data. 1980;Wiley, New York.
44. Bremner C.G., Demeester T.R. Proceedings from an international conference on ablation therapy for Barrett's mucosa. Brittany, France, 31 August-2 September 1997. Dis Esophagus. 11:1998;1-27.
45. Overholt B.F., Panjehpour M., Haydek J.M. Photodynamic therapy for Barrett's esophagus Follow-up in 100 patients . Gastrointest Endosc. 49:1999;1-7.
46. Sampliner R.E., Fennerty B., Garewal H.S. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation Preliminary results . Gastrointest Endosc. 44:1996;532-535.
47. Sontag S.J., Schnell T.G., Chejfec G., et al. High grade dysplasia Surveillance endoscopy once a year is sufficient in most patients . Gastroenterology. 116:1999;G1334. (abstract).
48. Weston A.P., Sharma P., Topalovski M., et al. Prospective long-term follow-up of Barrett's high-grade dysplasia Risky business . Gastroenterology. 116:1999;G1541. (abstract).
49. Sontag S.J., Schnell T., Chejfec G., et al. Barrett's, low grade dysplasia and fear Yearly endoscopy is not justified: Surveillance every 2-3 years detects all cancers early . Gastroenterology. 116:1999;A316. (abstract).
50. Shankey T.V., Rabinovitch P.S., Bagwell B., et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology [published erratum appears in Cytometry 1993;14:842]. Cytometry. 14:1993;472-477.
51. Coon J.S., Paxton H., Lucy L., et al. Interlaboratory variation in DNA flow cytometry. Results of the College of American Pathologists' Survey. Arch Pathol Lab Med. 118:1994;681-685.
52. Danesi D.T., Spanò M., Altavista P., et al. Quality control study of the Italian Group of Cytometry on Flow Cytometry DNA Content Measurements II. Factors affecting inter- and intralaboratory variability . Cytometry. 30:1997;85-97.
53. Bergers E., Montironi R., van Diest P.J., et al. Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometric DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Hum Pathol. 27:1996;553-560.
54. Melville D.M., Jass J.R., Shepherd N.A., et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology. 95:1988;668-675.
55. Begg C.B., Cramer L.D., Hoskins W.J., et al. Impact of hospital volume on operative mortality for major cancer surgery [see comments]. JAMA. 280:1998;1747-1751.
56. Patti MG, Corvera CU, Glasgow RE, et al. A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998;186-92.